TrakCel & McKesson partner to help commercialize gene & cell therapy

By Nikita Chaurasia  Date: 2019-09-13

TrakCel & McKesson partner to help commercialize gene & cell therapy
  • The combination of these two product suites is designed specifically for the growing number of developers that are nearing the commercial launch of gene and cell therapies.
  • The integrated platform allows the product scale-up towards market delivery including automatic product-specific workflow scheduling across multiple care team members and supply chain partners.

McKesson, a leading provider of patient access support, third-party logistic (3PL) services as well as specialty pharmacy solutions, and TrakCel, software developing firm for gene and cell therapy orchestration and supply chain tracking systems, reportedly announced a collaboration to help late-stage developers of gene and cell therapy.

The collaboration will combine both companies’ patient access services and supply chain tracking to allow a more effective path for the industry players to develop next-gen commercial therapies.

Integrating TrakCel’s personalized drug orchestration software and data tracking system with the capabilities of McKesson’s current high-touch platform for patients, as well as both the companies’ support and expertise, will give an end-to-end solution for the gene and cell therapy industry to manage the entirety of the therapeutic supply chain.

McKesson and TrakCel would start by developing a basic solution design. Both these integrated solutions will further be offered to individual company clients which would then benefit specifically from this combined solution.

The combination of these two product suites is particularly designed for the growing number of developers that are approaching commercial launch of their gene and cell therapies. The integrated platform allows the product scale-up towards market delivery.

This also involves automated scheduling of product-centric workflows across numerous care team members and supply chain partners, and a validated tracking of chain-of-identity to ensure delivery of the right drug product. These capabilities guarantee that the patient gets the right, uncompromised treatment at the correct time.

Layne Martin, VP/GM of Specialty Distribution Solutions at McKesson Life Sciences stated that the integrated system would help manufacturers and prescribers work together in a seamless manner to ensure that right patient always gets the right therapeutic product and at the correct time.

Source credit: https://www.businesswire.com/news/home/20190911005059/en/McKesson-TrakCel-Launch-Innovative-Collaboration-Support-Commercialization

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

U.K. might ease lockdown restrictions following drop in COVID-19 cases

U.K. might ease lockdown restrictions following drop in COVID-19 cases

By Nikita Chaurasia

British Prime Minister Boris Johnson is reportedly planning to further ease lockdown restrictions in the United Kingdom. This announcement comes after Britain witnessed a drop in the daily death toll and case count, primarily due to rapid vaccination...

Maruti Suzuki India prolongs maintenance shutdown over COVID-19 fears

Maruti Suzuki India prolongs maintenance shutdown over COVID-19 fears

By Nikita Chaurasia

Maruti Suzuki India Limited has reportedly extended its maintenance shutdown from May 9th to May 16th amidst rising COVID-19 cases across the country. However, it is difficult to ascertain whether the intention behind the extended shutdown is to guar...

Amazon sets tougher rules for its delivery service partners’ employees

Amazon sets tougher rules for its delivery service partners’ employees

By Nikita Chaurasia

Amazon is known for closely managing its staff and contractors, and it also seeks to control the employees of the companies in which it works. Reportedly, the company has updated its policies for Amazon’s delivery partners wherein it lays out d...

BMW, Ford lead Solid Power’s USD 130 million Series B funding round

BMW, Ford lead Solid Power’s USD 130 million Series B funding round

By Nikita Chaurasia

Solid Power Inc., a leading U.S-based producer of solid-state batteries has reportedly secured USD 130 million in the Series B funding round led by renowned car makers namely Ford Motor Company and BMW Group.  These funds will be used to develo...

Pfizer donates COVID-19 treatment drugs worth USD 70 million to India

Pfizer donates COVID-19 treatment drugs worth USD 70 million to India

By Nikita Chaurasia

Reportedly, American multinational pharmaceutical firm Pfizer Inc. has extended a helping hand to India in the battle against Covid-19, sending drugs worth USD 70 million to the country. The company is also in discussion with the Indian government to...